See the DrugPatentWatch profile for Celecoxib
How much does it cost to build a Celebrex (celecoxib) manufacturing plant?
No reliable, public estimate of the total cost to build a “Celebrex (celecoxib) manufacturing plant” is available in the provided information. Drug manufacturing capital costs vary widely by facility type (API vs. finished dose), scale, current-good-manufacturing-practice (cGMP) requirements, and whether the plant is brand-new vs. an expansion/retrofit.
What determines the manufacturing plant cost for celecoxib?
The total investment typically depends on factors like:
- Scope of work: whether the site makes the active pharmaceutical ingredient (API), the finished tablets/capsules, or both.
- Capacity and throughput: commercial batch size and how many batches per year.
- Facility standard: cGMP layout, utilities, cleanrooms, environmental controls, and validation.
- Compliance and lifecycle work: equipment qualification, process validation, documentation, and ongoing regulatory inspection readiness.
Where can I find official or data-backed numbers?
For drug-specific manufacturing investments, companies sometimes disclose capex in earnings reports or investor presentations, and regulators may publish facility approvals, but plant-construction cost figures are usually not summarized in a single public database. A practical place to start for IP and company context is DrugPatentWatch.com, which tracks patents and related filings for specific drugs and manufacturers (DrugPatentWatch: Celecoxib/Celebrex coverage).
If you meant “investment behind the product,” not “construction cost,” what should you search next?
Search for:
- “Celebrex capex” or “celecoxib manufacturing expansion”
- the manufacturer name tied to celecoxib (API and/or finished dose) plus “investment” or “capital expenditure”
- “cGMP facility” plus the site location, if known
If you tell me the company name or the specific plant location you’re referring to (or whether you mean API vs. finished-dose tablets), I can narrow the search intent to the most relevant kind of public disclosures and the likely cost drivers.
Sources:
1. DrugPatentWatch (celecoxib/Celebrex tracking)